KR20100035961A - Composition of gongjindan comprising nono powder of jinseung - Google Patents
Composition of gongjindan comprising nono powder of jinseung Download PDFInfo
- Publication number
- KR20100035961A KR20100035961A KR1020080095365A KR20080095365A KR20100035961A KR 20100035961 A KR20100035961 A KR 20100035961A KR 1020080095365 A KR1020080095365 A KR 1020080095365A KR 20080095365 A KR20080095365 A KR 20080095365A KR 20100035961 A KR20100035961 A KR 20100035961A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- powder
- present
- musk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000843 powder Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims description 9
- 239000009691 Gongjin-dan Substances 0.000 title 1
- 241000208340 Araliaceae Species 0.000 claims abstract description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 22
- 235000008434 ginseng Nutrition 0.000 claims abstract description 22
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 19
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 14
- 241000209020 Cornus Species 0.000 claims abstract description 14
- 210000003056 antler Anatomy 0.000 claims abstract description 14
- 239000002245 particle Substances 0.000 claims abstract description 14
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 9
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 9
- 238000009826 distribution Methods 0.000 claims abstract description 9
- 241001482592 Oreamnos americanus Species 0.000 claims abstract description 8
- 229930006000 Sucrose Natural products 0.000 claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 8
- 239000005720 sucrose Substances 0.000 claims abstract description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 17
- 239000010931 gold Substances 0.000 claims description 15
- 229910052737 gold Inorganic materials 0.000 claims description 15
- 240000002045 Guettarda speciosa Species 0.000 claims description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 6
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 6
- 241000283074 Equus asinus Species 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 241000282994 Cervidae Species 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 241001094255 Elytraria Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001416180 Moschidae Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZEASOXUPPLSUSE-UHFFFAOYSA-N butanedioic acid;sulfane Chemical compound S.OC(=O)CCC(O)=O ZEASOXUPPLSUSE-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- -1 loganine and saponin Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- AMBQHHVBBHTQBF-DLXIZZNVSA-N methyl 6-hydroxy-7-methyl-1-[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate Chemical compound C12C(C)C(O)CC2C(C(=O)OC)=COC1O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O AMBQHHVBBHTQBF-DLXIZZNVSA-N 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 1~400 ㎚의 입도분포를 갖도록 미분쇄된 산양산삼 분말 1 내지 100 중량부, 녹용 10 중량부, 당귀 10 중량부, 산수유 10 중량부, 숙지황 10 중량부, 사향 1.8 중량부, 패모 2.4 중량부, 패모 2.4 중량부, 귤피 2.4 중량부, 오미자 2.4 중량부 및 초석잠 2.4 중량으로 이루어진 산양산삼 분말을 함유하는 공진단으로서 인체흡수율을 향상하여 적은 양으로도 신속하고 양호한 효능을 발현하는 공진단에 관한 것이다.The present invention is 1 to 100 parts by weight of finely divided mountain goat ginseng powder, 10 parts by weight of antler, 10 parts by weight, cornus oil 10 parts by weight, 10 parts by weight of sucrose, 10 parts by weight of musk, musk 1.8 parts by weight, with a particle size distribution of 1 ~ 400 nm Resonator stage containing Sanyangsan ginseng powder consisting of 2.4 parts by weight, 2.4 parts by weight, 2.4 parts by weight of tangerine, 2.4 parts by weight of Schisandra chinensis and 2.4 parts by weight of follicles. It is about.
산양산삼, 분말, 공진단 Goyang ginseng, powder, resonant stage
Description
본 발명은 산양산삼 분말을 함유하는 공진단 조성물에 관한 것으로서, 좀더 상세하게는 1~400 ㎚의 입도분포를 갖도록 미분쇄된 산양산삼 분말 1 내지 100 중량부, 녹용 10 중량부, 당귀 10 중량부, 산수유 10 중량부, 숙지황 10 중량부, 사향 1.8 중량부, 패모 2.4 중량부, 패모 2.4 중량부, 귤피 2.4 중량부, 오미자 2.4 중량부 및 초석잠 2.4 중량으로 이루어진 산양산삼 분말을 함유하는 공진단으로서 인체흡수율을 향상하여 적은 양으로도 신속하고 양호한 효능을 발현하는 공진단에 관한 것이다.The present invention relates to a resonant stage composition containing a mountain goat ginseng powder, and more particularly, 1 to 100 parts by weight of uncultivated goat ginseng powder to have a particle size distribution of 1 ~ 400 nm, 10 parts by weight of deer antler, 10 parts by weight of Angelica, Resonator stage containing goat's ginseng powder consisting of 10 parts by weight of cornus oil, 10 parts by weight of sucrose sulfur, 1.8 parts by weight of musk, 2.4 parts by weight of musk, 2.4 parts by weight of famo, 2.4 parts by weight of citrus fruit, 2.4 parts by weight of Schisandra chinensis and 2.4 parts by weight The present invention relates to a resonator stage that improves absorption and expresses fast and good efficacy even in a small amount.
통상 공진단은 사향, 녹용, 당귀, 산수유 등의 귀한 약재로 제조되는 것으로 중국 원나라 때부터 유래되었으며 청심원, 경옥고와 함께 3대 명방으로 불릴 정도로 일반 서민이 접하기 힘든 보약으로 인식된다. 동의보감에 따르면"체질이 선천적으로 허약하더라도 본 방제는 하늘이 내려준 원기를 굳게 해 수승하강(水昇火降)하게 해 자연히 백병이 생기지 않게 하는 효능을 가졌다"고 기록돼 있을 정도로 보약 중의 보약으로 알려져 있다. 공진단의 활용을 살펴보면 노화를 방지하고 질병을 예 방하는 경우, 수술이나 큰 병으로 원기가 쇠약해진 경우, 정신적 신체적 과로로 기력이 저하된 경우, 만성 피로가 심하여 휴식으로도 회복이 더딘 경우, 선천적으로 체질이 약한 경우, 혈액순환 저하로 몸이 무겁고 저린 경우, 신경이 예민하여 어지럼증과 불면증이 있는 경우, 과다한 스트레스와 음주로 간 기능이 약화된 경우 등에 유용하다. 공진단의 주요한 4가지 한약재는 사향, 녹용, 당귀, 산수유이지만 복용하는 사람의 체질에 따라 인삼(홍삼), 숙지황 등 여러 다른 한약재를 첨가해 만드는 것이 가능하다. 인삼은 양기를 끌어올리는 성분이 많아 사상체질로 소음인에게 적절하다. 숙지황은 현삼과에 속한 생지황(生地黃)의 뿌리를 반복하여 건조하고 찌고 건조한 것으로서 보혈 기능이 필요한 경우 배합된다. 여기에 심신의 안정과 중풍 예방효과가 있는 금박을 입혀 만드는 공진단은 본래 체질이 허약한 사람의 면역력과 저항력을 길러주는데 효과가 뛰어나다. 그러나 금박은 사람에 따라 복용 거부감이나 위장장애를 초래할 수 있을 뿐 아니라 비교적 많은 양이 투입되므로 제조원가를 상승시키는 요인이 된다.Normally, the resonator stage is manufactured with precious medicines such as musk, deer antler, donkey, and cornus oil. It is derived from the Chinese Yuan Dynasty and is recognized as a medicine that is difficult to be seen by the common people. According to the agreement, it is said that "Even if the constitution is inherently fragile, this remedy has the effect of strengthening the energy given by the sky and making it descend so that it does not occur naturally." Known. The use of resonant stages prevents aging and prevents disease, when energy is weakened by surgery or a major illness, when energy is reduced due to mental and physical overwork, when chronic fatigue is so slow that recovery is slow even after rest. It is useful when the constitution is weak, when the body is heavy and stinged due to decreased blood circulation, when the nerves are sensitive and have dizziness and insomnia, and when the liver function is weakened by excessive stress and drinking. The four main herbal medicines of the resonant stage are musk, antler, tangui, and cornus, but depending on the nature of the person taking it, it is possible to add various other herbs such as ginseng (red ginseng) and succinate sulfur. Ginseng has a lot of ingredients to raise yanggi sasang constitution suitable for the noise person. Sukjihwang is a dry, steamed and dry by repeating the roots of raw jihwang (生地黄) belonging to the Hyunsam family is mixed when necessary for blood function. In addition, the resonator, which is made of gold leaf, which has the effect of stabilizing the mind and body, prevents paralysis, and is excellent in cultivating immunity and resistance of the inherently weak body. However, gold leaf can cause rejection or gastrointestinal disorders in some people, and a relatively large amount is added to increase the manufacturing cost.
본 발명은 상기한 점에 착안하는 것으로서 인체흡수율을 향상하여 적은 양으로도 신속하고 양호한 효능을 발현하는 나미분쇄된 산양산삼 분말을 함유하는 공진단을 제공하는 것을 그 목적으로 한다.It is an object of the present invention to provide a resonator stage containing nami-pulverized goats' ginseng powder, which improves human absorption and expresses fast and good efficacy even in a small amount.
본 발명은 1~400 ㎚의 입도분포를 갖도록 미분쇄된 산양산삼 분말 1 내지 100 중량부, 녹용 10 중량부, 당귀 10 중량부, 산수유 10 중량부, 숙지황 10 중량부, 사향 1.8 중량부, 패모 2.4 중량부, 패모 2.4 중량부, 귤피 2.4 중량부, 오미자 2.4 중량부 및 초석잠 2.4 중량으로 이루어진 산양산삼 분말을 함유하는 공진단 조성물에 관한 것이다.The present invention is 1 to 100 parts by weight of finely divided mountain goat ginseng powder, 10 parts by weight of antler, 10 parts by weight, cornus oil 10 parts by weight, 10 parts by weight of sucrose, 10 parts by weight of musk, musk 1.8 parts by weight, with a particle size distribution of 1 ~ 400 nm It relates to a resonant stage composition containing a mountain goat ginseng powder consisting of 2.4 parts by weight, 2.4 parts by weight of femdom, 2.4 parts by weight of tangerine, 2.4 parts by weight of Schisandra chinensis and 2.4 parts by weight of salt.
본 발명의 공진단은 나노입자로 파쇄된 산양산삼 분말이 함유되어 있어 인체 흡수율이 월등하고 표면적이 넓어 적은 양으로도 큰 효과를 나타낸다. 또한 본 발명의 공진단은 나노순금이 함유되기 때문에 금이 지니는 심신안정 및 관절염 예방 등 동의보감에 따른 효능도 향상된다. The resonator stage of the present invention contains the acid-produced ginseng powder crushed with nanoparticles, so that the human body absorption rate is excellent and the surface area is wide, thereby showing a large effect even in a small amount. In addition, since the resonator stage of the present invention contains nano-pure gold, the efficacy according to the consent of the consent, such as mental and mental stability and arthritis prevention of gold is also improved.
본 발명은 녹용, 사향, 당귀, 산수유를 주재로 하여 일정 크기의 구형환, 분말 또는 캡슐로 생성된 공진단에 있어서 1~400 ㎚의 입도분포를 갖도록 미분쇄된 산양산삼 분말 1 내지 100 중량부, 녹용 10 중량부, 당귀 10 중량부, 산수유 10 중량부, 숙지황 10 중량부, 사향 1.8 중량부, 패모 2.4 중량부, 패모 2.4 중량부, 귤피 2.4 중량부, 오미자 2.4 중량부 및 초석잠 2.4 중량으로 이루어진 것을 특징으로 하는 산양산삼 분말을 함유하는 공진단 조성물에 관한 것이다.The present invention is 1 to 100 parts by weight of pulverized mountain goat ginseng powder to have a particle size distribution of 1 ~ 400 nm in the resonant stage produced by a spherical ring, powder or capsule of a certain size, mainly antler, musk, donkey, cornus milk 10 parts by weight, Angelica 10 parts by weight, cornus oil 10 parts by weight, sucrose sulfur 10 parts by weight, musk 1.8 parts by weight, famo 2.4 parts by weight, famo 2.4 parts by weight, tangerine 2.4 parts by weight, Schisandra chinensis and 2.4 wt. It relates to a resonant stage composition containing a ginseng powder.
본 발명의 공진단 조성물은 순도 99% 이상의 순금을 분말로 파쇄하여 미량으로 도포하여 제조되는 것을 특징으로 한다.The resonator stage composition of the present invention is characterized by being produced by pulverizing pure gold with powder of 99% or more in a small amount.
본 발명의 양산삼 분말을 함유하는 공진단 조성물에서 순금은 1~400 ㎚의 입도분포를 갖도록 미분쇄된 것을 사용하는 것이 바람직하다. 산본 발명의 양산삼 분 말을 함유하는 공진단은 사향, 녹용, 당귀, 산수유 등을 부재료로 사용한다. 본 발명에서 사용하는 사향은 사향사슴 숫컷의 사향낭에서 생성되는 방향성분으로 무스콘 1-2%가 주성분 이고, 안드로스탄계 성분(성홀몬계통) 등의 10여종이 알려져 있으나 약효성분은 미상이다. 본 발명에서 사용하는 사향은 중추신경계 특히 호흡중추 및 심장을 흥분시켜 심장기능을 향진시키고 혈압강하작용이 있다. 본 발명에서 사용하는 녹용은 사슴의 골화되지 않은 어린 뿔로 아미노산, 지질, 당성분, 미량원소 및 그 밖의 성분을 포함한 것으로 알려져 있다. 본 발명에서 사용하는 녹용은 필수 아미노산을 포함한 16종의 아미노산으로 분리되고, 글루코스 등의 당성분이 함유되어 있다. 본 발명에서 사용하는 녹용은 간장계, 면역계, 심혈관계, 노화, 스트레스, 당대사, 조혈작용 등에 대한 효능이 있다. In the resonant stage composition containing the mass production ginseng powder of the present invention, the pure gold is preferably used that is finely ground to have a particle size distribution of 1 ~ 400 nm. The resonator stage containing the Yangsan ginseng powder of the present invention uses musk, deer antler, Angelica, cornus oil, etc. as submaterials. The musk used in the present invention is a fragrance component produced in the musk sac of male musk deer with 1-2% of moussecon as the main component, and about 10 species such as androstane-based ingredients (sex holocalic) are unknown, but the active ingredient is unknown. The musk used in the present invention stimulates the central nervous system, especially the respiratory center and heart, thereby promoting heart function and lowering blood pressure. Deer antler used in the present invention is known to include amino acids, lipids, sugar components, trace elements, and other components as the young horns of deer. The antler used in the present invention is separated into 16 kinds of amino acids including essential amino acids, and contains sugar components such as glucose. Deer antler used in the present invention has an effect on the liver system, immune system, cardiovascular system, aging, stress, glucose metabolism, hematopoiesis and the like.
본 발명에서 사용하는 당귀는 방향성분인 정유및 데쿠신, 진정작용하는 베타시토스테롤, 자당, 니코틴산, 엽산 등의 성분으로 구성되어 있다. 본 발명에서 사용하는 당귀는 각종 여성 질환, 생리불순, 생리통, 빈혈, 자궁 발육 부진, 산후 혈액 부족, 갱년기 장애 등에 두루 효과가 있고 여성 호르몬 분비를 원활하게 도와주는 작용이 있다. 본 발명에서 사용하는 산수유는 과실과 잎에서 각각 성분과 맛이 다르기는 하지만 로가닌, 사포닌 등의 배당체와 코르닌, 사과산, 포도주산, 비타민A 등이 함유되어 있다. 본 발명에서 사용하는 산수유 성분 중 코르닌은 신진 대사에 활력을 향상 시켜주며 항당뇨효과가 추정되는 물질도 포함하고 있다. 이외에 본 발명의 공진단의 주재로 인삼 또는 홍삼, 숙지향, 오가피, 천문동 등을 사용할 수도 있는 것은 종래의 공진단의 제조방법과 동일하다. Angelica used in the present invention is composed of components such as essential oils and decousins, sedating beta sitosterol, sucrose, nicotinic acid, folic acid and the like as aromatic components. Angelica used in the present invention is effective in various female diseases, menstrual disorders, menstrual pain, anemia, poor uterine development, postpartum blood deficiency, menopausal disorders, etc., and helps to secrete female hormones smoothly. The cornus oil used in the present invention contains glycosides such as loganine and saponin, cornine, malic acid, uric acid, vitamin A, and the like, although the ingredients and taste of the fruit and leaves are different. Cornine in the cornus component used in the present invention improves vitality in metabolism, and also includes substances in which antidiabetic effects are estimated. In addition, ginseng or red ginseng, succinct flavor, scabies, astronomical dong, and the like may be used as the main part of the resonant stage of the present invention, which is the same as the conventional resonator stage manufacturing method.
본 발명은 1~400 ㎚의 입도분포를 갖도록 미분쇄된 산양산삼 분말 1 내지 100 중량부, 녹용 10 중량부, 당귀 10 중량부, 산수유 10 중량부, 숙지황 10 중량부, 사향 1.8 중량부, 패모 2.4 중량부, 패모 2.4 중량부, 귤피 2.4 중량부, 오미자 2.4 중량부 및 초석잠 2.4 중량을 배합하여 제조한다. The present invention is 1 to 100 parts by weight of finely divided mountain goat ginseng powder, 10 parts by weight of antler, 10 parts by weight, cornus oil 10 parts by weight, 10 parts by weight of sucrose, 10 parts by weight of musk, musk 1.8 parts by weight, with a particle size distribution of 1 ~ 400 nm It is prepared by combining 2.4 parts by weight, 2.4 parts by weight of famo, 2.4 parts by weight of tangerine, 2.4 parts by weight of Schizandra chinensis and 2.4 parts by weight of salty nap.
본 발명의 양산삼 분말을 함유하는 공진단은 육계, 부자, 오미자, 귤피를 혼합한 보조재를 배합하고, 순도 99% 이상의 순금을 분말로 파쇄하여 미량으로 도포하여서 제조된다. 본 발명에서 사용하는 순금은 1~400 ㎚의 입도분포를 갖도록 미분쇄된 것을 사용하는 것이 바람직하다. The resonator stage containing the mass production ginseng powder of the present invention is prepared by blending auxiliary materials containing broiler, rich man, Schisandra chinensis and tangerine, and crushing pure gold with a purity of 99% or more in powder to apply a small amount. As the pure gold used in the present invention, it is preferable to use finely ground one having a particle size distribution of 1 to 400 nm.
계수나무의 껍질 말린 것을 육계라하고 작은 가지의 껍질 즉 육계보다 얇은 것을 계피라 하며 가느다란 가지를 썰어 말린 것을 계지라고 한다. 육계는 민간에서 수정과 만들 때 쓰이는 계피의 한약명으로서 건위작용, 억균작용, 혈액순환작용이 있다. 기본적인 인체의 화가 부족하여 손발과 아랫배가 차서 나타나는 제증상에 널리 활용되고 있다. 독성이 강한 것으로 알려진 부자(附子)는 속을 따뜻하게 하는 효과로 한방에서 사용되는데, 이는 hygenamine이라는 성분이 교감신경흥분제로서 심장을 흥분시키는 작용 때문이라고 한다. 이는 맥이 끊어질 듯 약할 때 양기(陽氣)를 돌려놓는 구급약이지만 매우 더운 약으로 독성이 강하며 잘못 사용했을 경우 생명에 치명적일 수 있으므로 매우 제한적으로 사용한다. The dried bark of cassia is called broiler, and the bark of small branches, thinner than broiler, is called cinnamon. Broiler chicken is the name of the cinnamon that is used in fertilization and making in the private sector. Lack of basic human upset and is widely used in the symptoms that appear cold hands and feet and belly. The rich, known to be toxic (附子) is used in herbal medicine to warm the inside, because the hygenamine ingredient sympathetic stimulant action to excite the heart. This is a paramedical drug that turns yang yang (yang 氣) when weak as if the break is a very hot drug is very toxic and can be fatal if used incorrectly, so use it very limitedly.
본 발명에서 사용하는 오미자는 신맛, 쓴맛, 단맛, 매운맛, 짠맛의 다섯가지 맛을 낸다고 하여 붙여진 이름이며, 일반성분은 수분 80%, 지방 1%, 단백질 1.2%, 총당함량 14%로 구성된다. 본 발명에서 사용하는 오미자에서 과즙내 당은 과당, 설 탕, 포도당, 맥아당이 함유되고, 유기산은 구연산, 주석산, 사과산, 수산(蓚酸), 숙신산, 초산, 젖산이 함유되어 있다. 차로 다려 마셔도 간장과 신장등과 같은 장기를 튼튼히 하고 강장, 당뇨병, 감기, 성기능감퇴, 기관지 등에 효과가 있다. 본 발명에서 사용하는 오미자는 더운물에 불리거나 끓이면 떫은 맛과 신맛이 강해지는 점에 주의한다. 본 발명에서 사용하는 오미자는 장기간 복용하면 머리가 맑아지고 피로 회복이 빠르고 혈액중의 혈당치를 내려주는 효과도 있다.Schisandra chinensis used in the present invention is a name given to give five flavors of sour, bitter, sweet, spicy, salty, the general ingredient consists of 80% moisture, 1% fat, 1.2% protein, 14% total sugar. In the Schizandra chinensis used in the present invention, the sugar in the juice contains fructose, sugar, glucose and maltose, and the organic acid contains citric acid, tartaric acid, malic acid, fish acid, succinic acid, acetic acid and lactic acid. Drinking tea to strengthen the organs, such as liver and kidneys, and tonic, diabetes, cold, sexual dysfunction, bronchial effect is effective. Note that the Schizandra chinensis used in the present invention is soaked in hot water or boiled so that its astringent taste and sour taste become stronger. Schisandra chinensis used in the present invention has a long term effect in clearing the head, recovering from fatigue, and lowering blood sugar levels in the blood.
귤껍질을 말린 것으로 신선한 것은 귤피, 오래된 것은 진피라고 하는데 오래 된 것일수록 좋은 약재로 취급된다. 본 발명에서 사용하는 귤피의 성질은 따뜻하고 무독하며 맛은 맵고 쓰다. 본 발명에서 사용하는 귤피의 성분중 리모넨(limonene)은 정유의 90% 이상을 차지하며 플라보노이드(flavonoids) 성분도 다량 함유하고 있다. 본 발명에서 사용하는 귤피의 주 약리작용은 리파제(lipase)의 활성증가, 항알레르기 효과, 자궁근의 수축 억제, 진정효과, 모세혈과 투과성 억제와 모세혈관 강화에 의한 동맥경화 및 고혈압예방 효과 등이다. 최근 실험결과 혈중 콜레스테롤을 낮추는 역할을 한다는 보고도 있다. 본 발명에서 사용하는 귤피는 특히 피할 사람도 없는 약재이고 단맛도 지니므로 사용상에 제한을 두지 않는다.Dried tangerine peel, the fresh one is tangerine, the old one is called dermis, the older one is treated as a good medicine. The properties of the tangerine used in the present invention are warm and non-toxic and the taste is hot and bitter. Limonene (limonene) of the components of the tangerine used in the present invention occupies more than 90% of the essential oil and contains a large amount of flavonoids (flavonoids). The main pharmacological action of the tangerine used in the present invention is increased lipase activity, anti-allergic effect, suppression of contraction of uterine muscle, sedative effect, arteriosclerosis and hypertension prevention effect by capillary and permeability inhibition and capillary strengthening, etc. to be. Recent experiments have been reported to play a role in lowering blood cholesterol. The tangerine used in the present invention is not particularly limited because it has no sweetness and no sweetness.
본 발명에서 사용하는 패모는 백합목 백합과 여러해살이풀이며 비늘줄기가 흰색 육질이며 5∼6개의 비늘조각으로 되어 있고 둥글다. 원줄기는 곧게 자란다. 잎은 마주나거나 3개씩 돌려나고 줄모양이며 길이 10㎝ 정도로 끝이 뾰족하다. 잎자루는 없다. 꽃은 5월에 자주색으로 피고 윗부분의 잎겨드랑이에 1개씩 달린다. 꽃덮이조각은 6개로서 주걱모양 긴 타원형이고, 수술은 6개로 꽃잎보다 짧다. 암술 대는 3개로 갈라진다. 열매는 삭과이며 6개의 날개가 있다. 본 발명에서 사용하는 패모의 비늘줄기는 중국패모와 함께 진해제·거담제(祛痰劑) 또는 젖을 나오게 하거나 고름을 배출시키는 약으로 쓰인다. The femdom used in the present invention is a lily-lily and perennial herb, scaly stem white, 5-6 scaly pieces, and round. The main stem grows straight. The leaves are opposite each other, or turned 3 times, and have a line shape, and the ends are pointed about 10cm long. No petioles; Flowers bloom in purple in May and hang one on the upper leaf axil. The flower cover is 6 pieces, spatula is long oval, and the stamen is 6, shorter than the petal. The pistil stand splits into three. Fruit is capsule and has six wings. The scaly stem of the floss used in the present invention is used as an antitussive agent, an expectorant, or milk or a pus to discharge pus along with Chinese feces.
본 발명에서 사용하는 초석잠은 주성분이 탄수화물이며 이 탄수화물은 감자와 같은 전분이 아니라 모두 올리고당이다. 본 발명에서 사용하는 초석잠의 올리고당은 장속에서 유익한 세균을 길러 장의 기능을 좋게 한다. 본 발명에서 사용하는 초석잠은 장의 기능이 좋아지고 영양소의 흡수가 좋아지고 장내 세균에 유익하며 장이 깨끗해지면 뇌의 기능이 정상화된다. 본 발명에서 사용하는 초석잠은 주성분은 뇌세포를 활성화시키고 강화하는 물질이 있다.The cornerstone used in the present invention is a carbohydrate whose main component is carbohydrates, all of which are oligosaccharides, not starches such as potatoes. Oligosaccharides of the cornerstone used in the present invention to grow beneficial bacteria in the intestine to improve the function of the intestine. Cornerstones used in the present invention, the function of the intestine is improved, the absorption of nutrients is good, the intestinal bacteria are beneficial, and the intestine is clean, the brain function is normalized. The cornerstone used in the present invention is a substance that activates and strengthens brain cells.
이와 같은 본 발명의 공진단은 녹용, 당귀, 산수유, 인삼, 숙지황 등의 주재를 15-20wt%로 할 때 사향은 1.5-2.5wt%, 바람직하게는 2.4wt%로 하고, 여기에 보조재인 육계, 부자, 오미자, 귤피 혼합재는 중량 기준으로 10-15%를 배합하는 것이 바람직하다. 본 발명에서 사용하는 보조재에서 부자는 용량을 더욱 제한적으로 유지하는 반면 귤피는 완제품의 요구되는 관능도에 따라 폭넓은 배합비로 배합하는 것이 바람직하다.The resonator stage of the present invention has a musk ratio of 1.5-2.5 wt%, preferably 2.4 wt%, when the main ingredients such as deer antler, donkey, cornus, ginseng, and sucrose are 15-20 wt%. The rich, schisandra chinensis and tangerine mixture are preferably blended 10-15% by weight. In the auxiliary material used in the present invention, while the rich maintain a more limited capacity, it is preferable that the tangerine is formulated in a wide range of blending ratios depending on the required functionality of the finished product.
또한, 본 발명에서 사용하는 순금은 순도 99% 이상의 순금을 분말로 파쇄하여 미량으로 도포하여서 제조한다. 독성이 전혀없는 순금이 의학적으로 사용된 것은 류마티스, 관절염, 신경통 등의 주사로 쓴 것이 최초라 한다. 금은 인체의 면역체계에 영향을 미치는 것으로 알려져 있기 때문에 면역체계 이상으로 발병되는 질환인 류마티스, 관절염, 신경통, 신경안정, 해독, 피부정화에 효능이 있다고 알려 져 있다. 본 발명에 따른 공진단의 순금은 1~400 ㎚의 입도분포를 갖도록 미분쇄된 것을 사용하는 것이 바람직하다. 통상 입자의 크기가 작아질수록 표면으로 노출되는 분자의 수가 증가한다. 입자의 입경이 5nm가 되면 입자를 구성하는 분자 중 50%가 표면에 위치하게 되고, 입자의 크기가 2nm가 되면 그 비율은 90% 이른다. 표면에 위치한 분자의 비율이 높을수록 표면에너지의 결합에너지에 대한 비가 증대되어 생리학적 반응의 촉매역할이 활성화된다. 다만 순금의 입도를 어느 정도로 하는 가는 제조경비와 관련되어 유동적으로 결정할 수 있다. 순도 95% 이상인 순금을 1~400 ㎚ 크기의 분말로 하되 공진단 1개당 대략 0.001-0.1g의 범위에서 도포되도록 한다. 현재는 마이크로미터(㎛) 단위의 미분상태로 파쇄하기도 하지만 나노상태로 파쇄하여 제품을 만들 수 있다. In addition, the pure gold used in the present invention is produced by crushing the pure gold with a purity of 99% or more in powder to apply a small amount. It is the first time that pure gold, which has no toxicity, has been used medically by injections of rheumatism, arthritis and neuralgia. Since gold is known to affect the body's immune system, it is known to be effective for rheumatoid arthritis, arthritis, neuralgia, nerve stabilization, detoxification, and skin cleansing. The pure gold of the resonator stage according to the present invention is preferably used that is finely ground to have a particle size distribution of 1 ~ 400 nm. In general, the smaller the particle size, the greater the number of molecules exposed to the surface. When the particle size of the particles reaches 5 nm, 50% of the molecules constituting the particles are placed on the surface, and when the size of the particles reaches 2 nm, the ratio reaches 90%. The higher the proportion of molecules on the surface, the higher the ratio of surface energy to binding energy, which activates the catalytic role of the physiological reaction. However, the degree to which the grain size of pure gold can be determined can be fluidly determined in relation to manufacturing costs. The pure gold having a purity of 95% or more is made into a powder having a size of 1 to 400 nm, and is applied in the range of approximately 0.001-0.1 g per one resonator stage. Currently, it is crushed in the form of micrometers (μm), but the product can be made by crushing in the nano state.
본 발명의 공진단은 주재료와 보조재료를 교반한 다음 꿀이나 점착성 있는 녹말 등의 부형재로 혼합하여 일정 크기의 구형의 환을 만든다. 본 발명에서 사용하는 순금은 분말 상태 대신에 나노수용액 상태로 배합하거나 도포하는 것도 가능하며 나노 수용액을 사용하면 제조공정 간에 탈락에 의한 로스를 줄이는데 유리하다.The resonator stage of the present invention stirs the main material and the auxiliary material and then mixes it with an excipient such as honey or tacky starch to make a spherical ring of a certain size. Pure gold used in the present invention may be formulated or applied in a nanoaqueous solution instead of a powdered state, and the use of the nanoaqueous solution is advantageous in reducing loss due to dropping out between manufacturing processes.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080095365A KR20100035961A (en) | 2008-09-29 | 2008-09-29 | Composition of gongjindan comprising nono powder of jinseung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080095365A KR20100035961A (en) | 2008-09-29 | 2008-09-29 | Composition of gongjindan comprising nono powder of jinseung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100035961A true KR20100035961A (en) | 2010-04-07 |
Family
ID=42213690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080095365A Ceased KR20100035961A (en) | 2008-09-29 | 2008-09-29 | Composition of gongjindan comprising nono powder of jinseung |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20100035961A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160146572A (en) | 2015-06-11 | 2016-12-21 | 진용희 | Gongjindan of minimizing active component loss and method manufacturing thereof |
| KR102222753B1 (en) | 2020-10-30 | 2021-03-04 | 김성태 | Manufacturing method of agarwood gongjindan with excellent absorption rate in the body |
| KR20240113630A (en) | 2023-01-13 | 2024-07-23 | 최병국 | Method for maufacturing tablet containing musk |
| KR20240156657A (en) | 2023-04-20 | 2024-10-31 | (주)휴팜 | Manufacturing method of film-type gongjindan with excellent preservation and solubility |
-
2008
- 2008-09-29 KR KR1020080095365A patent/KR20100035961A/en not_active Ceased
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160146572A (en) | 2015-06-11 | 2016-12-21 | 진용희 | Gongjindan of minimizing active component loss and method manufacturing thereof |
| KR102222753B1 (en) | 2020-10-30 | 2021-03-04 | 김성태 | Manufacturing method of agarwood gongjindan with excellent absorption rate in the body |
| KR20240113630A (en) | 2023-01-13 | 2024-07-23 | 최병국 | Method for maufacturing tablet containing musk |
| KR20240156657A (en) | 2023-04-20 | 2024-10-31 | (주)휴팜 | Manufacturing method of film-type gongjindan with excellent preservation and solubility |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6077554B2 (en) | Wrapping fermentation method using medicinal flowers and skin external preparation composition using the method | |
| KR101090284B1 (en) | Drinks containing red ginseng and antler extract and preparation method thereof | |
| KR20130086682A (en) | Goljanghoebok sewage and 100 kinds of herbal extract ginseng antler andohgapideung deuringkeuje how mitjejo | |
| KR20160087114A (en) | Food additive containing flowers | |
| KR20040095000A (en) | Alcoholic liquor compositions suitable for physical constitution of user and method for preparing the same | |
| CN105695258A (en) | Female health wine containing lychee seed saponin | |
| CN103828954A (en) | Weight reducing tea and making method thereof | |
| KR20150040392A (en) | undiluted stevia liquid and the berages, and its manufacturing method | |
| CN106692675A (en) | Soft extract for nourishing qi and invigorating the circulation of blood, as well as preparation method and application thereof | |
| CN103125710A (en) | Bazhen tea for women | |
| KR20100035961A (en) | Composition of gongjindan comprising nono powder of jinseung | |
| CN104068177A (en) | Health-care life-lengthening natural plant tea | |
| KR101520332B1 (en) | Functional coffee having medicinal herb and manufacturing method thereof | |
| KR101999675B1 (en) | Herbal composition for the prevention and treatment of coronary heart disease | |
| KR100923043B1 (en) | Herbal herbal medicine blood pressure therapy and its manufacturing method | |
| CN107156829A (en) | A kind of full nutrition formula food suitable for hepatopath | |
| CN104719538A (en) | Preparation method of bamboo salt tea | |
| KR101694431B1 (en) | Mixed tea composition of herbal medicine having the improved taste, and preparation thereof | |
| KR100955826B1 (en) | Pills for improving and alleviating inflammatory diseases | |
| KR100469006B1 (en) | Process for preparing health beverage | |
| CN110584037A (en) | Food ginseng cream and preparation method thereof | |
| RU2792449C2 (en) | Composition of phytotea containing biologically active additives | |
| RU2496325C1 (en) | Composition for dragees preparation | |
| KR101290190B1 (en) | Composition of health supplement food containing mulberry and black sesame and method for manufacturing the composition | |
| KR101490793B1 (en) | Method of preparing tea composition, and tea composition therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20080929 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20101001 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20110523 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20101001 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |